Global Systemic Aspergillosis and Systemic Candidiasis Market (2024 Edition): Analysis By Type (Candidiasis, Aspergillosis), By Treatment Approach, By End User, By Region, By Country: Market Insights and Forecast (2020-2030)

Global Systemic Aspergillosis and Systemic Candidiasis Market (2024 Edition): Analysis By Type (Candidiasis, Aspergillosis), By Treatment Approach, By End User, By Region, By Country: Market Insights and Forecast (2020-2030)

Executive Summary

Azoth Analytics has released a research report titled “Global Systemic Aspergillosis and Systemic Candidiasis Market (2024 Edition)” which provides a complete analysis of the Global Systemic Aspergillosis and Systemic Candidiasis industry in terms of market segmentation By Type (Candidiasis, Aspergillosis), By Treatment Approach (Antifungal Medications, Combination Therapy, and Surgical Intervention) By End Users (Hospitals, Clinics, Other End-users) for the historical period of 2020-2023, the estimates of 2024 and the forecast period of 2025-2030.

The report analyses the Global Systemic Aspergillosis and Systemic Candidiasis Market by Region (Americas, Europe, Asia Pacific, Middle East & Africa) and 10 Countries (United States, Canada, Germany, United Kingdom, France, Italy, Spain, China, Japan, India). The Global Systemic Aspergillosis and Systemic Candidiasis market showcased growth at a CAGR of 3.62% during 2020-2023.

The market was valued at USD 7.18 Billion in 2023 which is expected to reach USD 9.62 Billion in 2030. Growing disposable income levels, particularly among affluent consumers, have fuelled demand for premium anti-aging Surgical Intervention and skincare products.

Aspergillosis and candidiasis are among the most common fungal infections worldwide, affecting individuals with compromised immune systems, such as transplant recipients, cancer patients

undergoing chemotherapy, and those with HIV/AIDS. These infections can manifest as severe pulmonary, bloodstream, or invasive infections, leading to substantial morbidity and mortality if not promptly diagnosed and treated.

Antifungal drugs continue to serve as the foundation for treating systemic aspergillosis and systemic candidiasis, with azoles, echinocandins, and polyenes representing the primary

treatment options. Combinations of these medications may be utilized in cases where standard therapy proves ineffective or to combat instances of emerging drug resistance. In certain

scenarios, such as invasive pulmonary aspergillosis or fungal endocarditis, surgical procedures may be warranted as adjunctive therapy.

The Global Systemic Aspergillosis and Systemic Candidiasis Market experiences momentum due to rising occurrences of fungal infections, improved diagnostic methods, heightened awareness among healthcare practitioners and individuals, and the expanding array of antifungal treatments. Furthermore, factors such as population aging, immunosuppressive treatments, and hospital- acquired transmissions bolster the market's expansion.

The market is characterized by intense competition among key players, including pharmaceutical companies, and healthcare organizations. These companies are continuously innovating and launching new products and solutions to meet the evolving needs of healthcare providers, laboratories, and patients.

Scope of the Report:

• The report analyses the Systemic Aspergillosis and Systemic Candidiasis Market by Value (USD Billion).
• The report analyses the Systemic Aspergillosis and Systemic Candidiasis Market by Region (Americas, Europe, Asia Pacific, Middle East & Africa) and 10 Countries (United States, Canada,

Germany, United Kingdom, France, Italy, Spain, China, Japan, India).

• The report presents the analysis of Systemic Aspergillosis and Systemic Candidiasis Market for the historical period of 2020-2023, the estimated year 2024 and the forecast period of 2025-2030.
• The report analyses the Systemic Aspergillosis and Systemic Candidiasis Market By Type (Candidiasis, Aspergillosis)
• The report analyses the Systemic Aspergillosis and Systemic Candidiasis Market By Treatment Approach (Antifungal Medications, Combination Therapy, and Surgical Intervention).
• The report analyses the Systemic Aspergillosis and Systemic Candidiasis Market By End Users (Hospitals, Clinics, and Other End Users).
• The key insights of the report have been presented through the frameworks of SWOT and Porter’s Five Forces Analysis. Also, the attractiveness of the market has been presented by region, By Type, By Treatment Approach and By End User.
• Also, the major opportunities, trends, drivers, and challenges of the industry has been analyzed in the report.
• The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include Sanofi, Cipla, Pfizer, GSK PLC, Novartis AG, Bayer AG, Merck & Co., Inc., F. Hoffmann-La Roche AG, Abbott Laboratories and Gilead Sciences, Inc.